2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

被引：1342

作者：

Hughes, WT

Armstrong, D

Bodey, GP

Bow, EJ

Brown, AE

Calandra, T

Feld, R

Pizzo, PA

Rolston, KVI

Shenep, JL

Young, LS

机构：

[1] St Jude Childrens Res Hosp, Memphis, TN 38105 USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[3] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Harvard Univ, Sch Med, Boston, MA USA

[5] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA

[6] Kuzell Inst Arthrit, San Francisco, CA USA

[7] Univ Manitoba, Winnipeg, MB, Canada

[8] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[9] CHU Vaudois, CH-1011 Lausanne, Switzerland

来源：

CLINICAL INFECTIOUS DISEASES | 2002年 / 34卷 / 06期

关键词：

D O I：

10.1086/339215

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This article, prepared by the Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guidelines Panel, updates guidelines established a decade ago by the Infectious Disease Society of America for the use of antimicrobial agents to treat neutropenic patients with unexplained fever [1].

引用

收藏

页码：730 / 751

页数：22

相关论文

共 195 条

[41] A PROSPECTIVE-STUDY COMPARING VANCOMYCIN AND TEICOPLANIN AS 2ND-LINE EMPIRIC THERAPY FOR INFECTION IN NEUTROPENIC PATIENTS [J].

CONYMAKHOUL, P ;

BROSSARD, G ;

MARIT, G ;

PELLEGRIN, JL ;

TEXIERMAUGEIN, J ;

REIFFERS, J .

BRITISH JOURNAL OF HAEMATOLOGY, 1990, 76 :35-40

[42] DISCONTINUATION OF INTRAVENOUS ANTIBIOTIC-THERAPY DURING PERSISTENT NEUTROPENIA IN PATIENTS RECEIVING PROPHYLAXIS WITH ORAL CIPROFLOXACIN [J].

CORNELISSEN, JJ ;

ROZENBERGARSKA, M ;

DEKKER, AW .

CLINICAL INFECTIOUS DISEASES, 1995, 21 (05) :1300-1302

[43] PROSPECTIVE MULTICENTRIC STUDY OF THE ETIOLOGY OF 1051 BACTEREMIC EPISODES IN 782 CANCER-PATIENTS [J].

COULLIOUD, D ;

VANDERAUWERA, P ;

VIOT, M ;

LASSET, C .

SUPPORTIVE CARE IN CANCER, 1993, 1 (01) :34-46

[44]

CRANE L, 1988, 28TH P M ICAAC LOS A, P114

[45] Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis [J].

Cruciani, M ;

Rampazzo, R ;

Malena, M ;

Lazzarini, L ;

Todeschini, G ;

Messori, A ;

Concia, E .

CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) :795-805

[46]

DALE DC, 1979, MEDICINE, V58, P128, DOI 10.1097/00005792-197903000-00002

[47] A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia [J].

Del Favero, A ;

Menichetti, F ;

Martino, P ;

Bucaneve, G ;

Micozzi, A ;

Gentile, G ;

Furno, P ;

Russo, D ;

D'Antonio, D ;

Ricci, P ;

Martino, B ;

Mandelli, F .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1295-1301

[48] Antibiotic treatment of febrile episodes in neutropenic cancer patients - Clinical and economic considerations [J].

deLalla, F .

DRUGS, 1997, 53 (05) :789-804

[49]

DEMARIE S, 1993, EUR J CLIN MICROBIOL, V12, P897

[50] CEFTAZIDIME COMPARED WITH PIPERACILLIN AND TOBRAMYCIN FOR THE EMPIRIC TREATMENT OF FEVER IN NEUTROPENIC PATIENTS WITH CANCER - A MULTICENTER RANDOMIZED TRIAL [J].

DEPAUW, BE ;

DERESINSKI, SC ;

FELD, R ;

LANEALLMAN, EF ;

DONNELLY, JP .

ANNALS OF INTERNAL MEDICINE, 1994, 120 (10) :834-844

← 1 2 3 4 5 6 7 8 9 10 →